AAPL325.07+8.22 (+2.59%) ▲|ABBV259.68+3.26 (+1.27%) ▲|ABT109.66-0.71 (-0.64%) ▼|ACN187.75-2.01 (-1.06%) ▼|ADBE288.74-4.06 (-1.39%) ▼|AMAT441.89-16.50 (-3.60%) ▼|AMD456.87-13.85 (-2.94%) ▼|AMGN432.62+2.74 (+0.64%) ▲|AMT175.81+0.11 (+0.06%) ▲|AMZN254.34-5.43 (-2.09%) ▼|AVGO369.35-0.99 (-0.27%) ▼|AXP324.37-5.80 (-1.76%) ▼|BA205.97-1.81 (-0.87%) ▼|BAC61.88-0.06 (-0.10%) ▼|BKNG197.78-1.31 (-0.66%) ▼|BLK1,128.07-27.54 (-2.38%) ▼|BMY66.88+0.07 (+0.10%) ▲|BNY159.62-1.67 (-1.03%) ▼|BRK-B504.49+0.46 (+0.09%) ▲|C132.22+0.60 (+0.46%) ▲|CAT775.29-22.18 (-2.78%) ▼|CL90.14+0.32 (+0.35%) ▲|CMCSA26.49-0.14 (-0.51%) ▼|COF211.57-2.95 (-1.37%) ▼|COP135.48+2.99 (+2.26%) ▲|COST945.20+1.31 (+0.14%) ▲|CRM257.75+0.21 (+0.08%) ▲|CSCO109.25-1.25 (-1.13%) ▼|CVS96.89+2.98 (+3.17%) ▲|CVX209.57+3.43 (+1.66%) ▲|DE668.09+13.18 (+2.01%) ▲|DHR207.42-6.14 (-2.88%) ▼|DIS106.84-0.71 (-0.66%) ▼|DUK119.94+0.03 (+0.02%) ▲|EMR147.92-4.52 (-2.97%) ▼|FDX320.70-6.70 (-2.05%) ▼|GD369.89-1.47 (-0.39%) ▼|GE330.54-5.17 (-1.54%) ▼|GEV891.14-7.39 (-0.82%) ▼|GILD148.62+2.28 (+1.56%) ▲|GM85.59-0.73 (-0.85%) ▼|GOOG332.21-3.20 (-0.95%) ▼|GOOGL335.40-3.95 (-1.16%) ▼|GS1,009.12-11.78 (-1.15%) ▼|HD319.73-8.10 (-2.47%) ▼|HON209.36-4.17 (-1.95%) ▼|IBM230.88-2.99 (-1.28%) ▼|INTC88.66-0.86 (-0.96%) ▼|INTU347.80-11.50 (-3.20%) ▼|ISRG367.98-8.89 (-2.36%) ▼|JNJ269.75+3.90 (+1.47%) ▲|JPM355.22-0.80 (-0.22%) ▼|KO88.12-0.56 (-0.63%) ▼|LIN482.96-6.62 (-1.35%) ▼|LLY1,163.21+6.48 (+0.56%) ▲|LMT545.22-12.56 (-2.25%) ▼|LOW201.02-3.68 (-1.80%) ▼|LRCX289.32-12.17 (-4.04%) ▼|MA585.27-4.04 (-0.69%) ▼|MCD261.51-0.17 (-0.07%) ▼|MDLZ61.85-0.22 (-0.35%) ▼|MDT92.73+2.08 (+2.29%) ▲|META580.80+8.46 (+1.48%) ▲|MMM169.99-1.84 (-1.07%) ▼|MO70.21+1.73 (+2.53%) ▲|MRK149.01+1.25 (+0.84%) ▲|MS211.93-1.39 (-0.65%) ▼|MSFT500.99-6.31 (-1.24%) ▼|MU941.30-17.43 (-1.82%) ▼|NEE82.45+0.11 (+0.13%) ▲|NFLX80.97-0.08 (-0.10%) ▼|NKE38.18-0.47 (-1.22%) ▼|NOW143.74-4.25 (-2.87%) ▼|NVDA218.33-2.17 (-0.98%) ▼|ORCL140.72-8.40 (-5.63%) ▼|PEP139.84-0.50 (-0.36%) ▼|PFE28.61+0.15 (+0.51%) ▲|PG146.19+1.07 (+0.74%) ▲|PLTR182.49-3.90 (-2.09%) ▼|PM189.36+2.06 (+1.10%) ▲|QCOM165.94-4.54 (-2.66%) ▼|RTX205.17-2.56 (-1.23%) ▼|SBUX105.51-0.74 (-0.70%) ▼|SCHW108.39-1.43 (-1.30%) ▼|SO87.86-0.14 (-0.16%) ▼|SPG212.14-0.18 (-0.08%) ▼|T26.11+0.22 (+0.83%) ▲|TMO602.10-15.00 (-2.43%) ▼|TMUS182.39+1.95 (+1.08%) ▲|TSLA357.15-10.80 (-2.94%) ▼|TXN251.54-9.37 (-3.59%) ▼|UBER75.45-0.20 (-0.26%) ▼|UNH395.02+5.61 (+1.44%) ▲|UNP289.90-10.77 (-3.58%) ▼|UPS102.06-2.17 (-2.08%) ▼|USB60.86-0.72 (-1.17%) ▼|V375.43-3.94 (-1.04%) ▼|VZ50.41+0.39 (+0.77%) ▲|WFC86.53+0.14 (+0.16%) ▲|WMT106.24+1.37 (+1.31%) ▲|XOM163.86+2.91 (+1.81%) ▲|AAPL325.07+8.22 (+2.59%) ▲|ABBV259.68+3.26 (+1.27%) ▲|ABT109.66-0.71 (-0.64%) ▼|ACN187.75-2.01 (-1.06%) ▼|ADBE288.74-4.06 (-1.39%) ▼|AMAT441.89-16.50 (-3.60%) ▼|AMD456.87-13.85 (-2.94%) ▼|AMGN432.62+2.74 (+0.64%) ▲|AMT175.81+0.11 (+0.06%) ▲|AMZN254.34-5.43 (-2.09%) ▼|AVGO369.35-0.99 (-0.27%) ▼|AXP324.37-5.80 (-1.76%) ▼|BA205.97-1.81 (-0.87%) ▼|BAC61.88-0.06 (-0.10%) ▼|BKNG197.78-1.31 (-0.66%) ▼|BLK1,128.07-27.54 (-2.38%) ▼|BMY66.88+0.07 (+0.10%) ▲|BNY159.62-1.67 (-1.03%) ▼|BRK-B504.49+0.46 (+0.09%) ▲|C132.22+0.60 (+0.46%) ▲|CAT775.29-22.18 (-2.78%) ▼|CL90.14+0.32 (+0.35%) ▲|CMCSA26.49-0.14 (-0.51%) ▼|COF211.57-2.95 (-1.37%) ▼|COP135.48+2.99 (+2.26%) ▲|COST945.20+1.31 (+0.14%) ▲|CRM257.75+0.21 (+0.08%) ▲|CSCO109.25-1.25 (-1.13%) ▼|CVS96.89+2.98 (+3.17%) ▲|CVX209.57+3.43 (+1.66%) ▲|DE668.09+13.18 (+2.01%) ▲|DHR207.42-6.14 (-2.88%) ▼|DIS106.84-0.71 (-0.66%) ▼|DUK119.94+0.03 (+0.02%) ▲|EMR147.92-4.52 (-2.97%) ▼|FDX320.70-6.70 (-2.05%) ▼|GD369.89-1.47 (-0.39%) ▼|GE330.54-5.17 (-1.54%) ▼|GEV891.14-7.39 (-0.82%) ▼|GILD148.62+2.28 (+1.56%) ▲|GM85.59-0.73 (-0.85%) ▼|GOOG332.21-3.20 (-0.95%) ▼|GOOGL335.40-3.95 (-1.16%) ▼|GS1,009.12-11.78 (-1.15%) ▼|HD319.73-8.10 (-2.47%) ▼|HON209.36-4.17 (-1.95%) ▼|IBM230.88-2.99 (-1.28%) ▼|INTC88.66-0.86 (-0.96%) ▼|INTU347.80-11.50 (-3.20%) ▼|ISRG367.98-8.89 (-2.36%) ▼|JNJ269.75+3.90 (+1.47%) ▲|JPM355.22-0.80 (-0.22%) ▼|KO88.12-0.56 (-0.63%) ▼|LIN482.96-6.62 (-1.35%) ▼|LLY1,163.21+6.48 (+0.56%) ▲|LMT545.22-12.56 (-2.25%) ▼|LOW201.02-3.68 (-1.80%) ▼|LRCX289.32-12.17 (-4.04%) ▼|MA585.27-4.04 (-0.69%) ▼|MCD261.51-0.17 (-0.07%) ▼|MDLZ61.85-0.22 (-0.35%) ▼|MDT92.73+2.08 (+2.29%) ▲|META580.80+8.46 (+1.48%) ▲|MMM169.99-1.84 (-1.07%) ▼|MO70.21+1.73 (+2.53%) ▲|MRK149.01+1.25 (+0.84%) ▲|MS211.93-1.39 (-0.65%) ▼|MSFT500.99-6.31 (-1.24%) ▼|MU941.30-17.43 (-1.82%) ▼|NEE82.45+0.11 (+0.13%) ▲|NFLX80.97-0.08 (-0.10%) ▼|NKE38.18-0.47 (-1.22%) ▼|NOW143.74-4.25 (-2.87%) ▼|NVDA218.33-2.17 (-0.98%) ▼|ORCL140.72-8.40 (-5.63%) ▼|PEP139.84-0.50 (-0.36%) ▼|PFE28.61+0.15 (+0.51%) ▲|PG146.19+1.07 (+0.74%) ▲|PLTR182.49-3.90 (-2.09%) ▼|PM189.36+2.06 (+1.10%) ▲|QCOM165.94-4.54 (-2.66%) ▼|RTX205.17-2.56 (-1.23%) ▼|SBUX105.51-0.74 (-0.70%) ▼|SCHW108.39-1.43 (-1.30%) ▼|SO87.86-0.14 (-0.16%) ▼|SPG212.14-0.18 (-0.08%) ▼|T26.11+0.22 (+0.83%) ▲|TMO602.10-15.00 (-2.43%) ▼|TMUS182.39+1.95 (+1.08%) ▲|TSLA357.15-10.80 (-2.94%) ▼|TXN251.54-9.37 (-3.59%) ▼|UBER75.45-0.20 (-0.26%) ▼|UNH395.02+5.61 (+1.44%) ▲|UNP289.90-10.77 (-3.58%) ▼|UPS102.06-2.17 (-2.08%) ▼|USB60.86-0.72 (-1.17%) ▼|V375.43-3.94 (-1.04%) ▼|VZ50.41+0.39 (+0.77%) ▲|WFC86.53+0.14 (+0.16%) ▲|WMT106.24+1.37 (+1.31%) ▲|XOM163.86+2.91 (+1.81%) ▲|
26.9 C
New York
Tuesday, September 1, 2026

Tag: therapy

newssourceFORcompanyinformationcontent1releasesmarket

Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson’s Disease

Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's Disease

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain...

TAIPEI, June 11, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...

Pleinement Givré Releases Industry Report Examining the Growing Role of Breathwork, Cold Therapy, and Contrast Therapy in Stress Management and Longevity

Founded by certified Wim Hof Method instructor Alexandre Tonnelier, the company runs accessible retreats across Brittany, the Loire Valley, and the French Alps — combining breathwork, ice bathing, contrast therapy, and a comprehensive approach to longevity for individuals and executives looking to transform their relationship to stress and to their health. 
Founded by certified Wim Hof Method instructor Alexandre Tonnelier, the company runs accessible retreats across Brittany, the Loire Valley, and the French Alps — combining breathwork, ice bathing, contrast therapy, and a comprehensive approach to longevity for individuals and executives looking to transform their relationship to stress and to their health.

NY Business Leaders Come Out in Force to Support Global Hope & Healing Via the Human-Animal Bond

NEW YORK, June 10, 2026 /PRNewswire/ -- Executives from New York's major investment banks and law firms packed the Edison Ballroom this past Wednesday...

Bismarck Women’s Health Expert Hosts Free Community Event to Help Women Understand Heavy and Painful Periods

Featuring Dr. Rhonda Schafer-McLean, a board-certified OB/GYN with more than 15 years of experience caring for women throughout North Dakota 
Featuring Dr. Rhonda Schafer-McLean, a board-certified OB/GYN with more than 15 years of experience caring for women throughout North Dakota

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026. 

Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform Technology

Access the segment here

Alteogen Showcases ALT-B4’s Potential to Transform ADC Development at World ADC Summit 2026

Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapyKey PointsSuperior PK: Subcutaneous administration of ADCs...

New Case Series on Umbilical Tissue in Plantar Fascia Applications Demonstrates Clinical Reproducibility

Case Series by Dr. Robert Parker, DPM, Published in Archives of Clinical...

Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company

Minami Maeda appointed as CEO to drive faster, more focused execution toward U.S. commercial launchMickey Mikitani will continue to provide strategic direction and remains...

Asante partners with Western University of Health Sciences to launch core rotation sites for medical students in southern Oregon

LEBANON, Ore., June 9, 2026 /PRNewswire/ -- In an effort to continue building the health care workforce pipeline in southern Oregon, Asante announced today a...

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers